Contact Ronnie

Speaking Engagements

  

Toxicity remains the single biggest hurdle in getting ADCs to market, and drug developers are striving to develop safer antibody drug conjugates while keeping efficacy high. Although ADCs have come far, there are still more advancements to be made, highlighted by the blockbuster Enhertu and the recently approved Elahere, both containing Black Box W

25-27 July 2023